This study is to investigate the inhibitory effect of different concentrations of zoledronic acid on the activity of osteoclasts, to obtain characteristics on inhibitory effect and to find the lowest effective concentration of zoledronic acid. Marrow cells of C57 mice (6 weeks) were cultured in vitro. Osteoclasts were induced by single nuclear cells. According to the concentration of zoledronic acid, we set up the experimental group with five different concentrations, i.e. 1×10–8 mol/L, 1×10–7 mol/L, 1×10–6 mol/L, 1×10–5 mol/L, and 1×10–4 mol/L. The control group did not contain any bisphosphonate. By tartrate resistant acid phosphatase staining, the number of multinuclear cells, cells through the filter and bone resorption lacune were counted. Five days after the cultivation, the number of multinuclear cells in the experimental group decreased with the increase of concentration of zoledronic acid. Inhibition on the formation of osteoclasts in vitro was effective at 1×10–6 mol/L. At the concentration of 1×10–5 mol/L, the effect of inhibition on migration of osteoclast and bone resorption was more obvious. The effect was further enhanced at concentration of 1×10–4 mol/L. However, the concentration and inhibition curves were gradually mild. The inhibitory effect on different concentrations of zoledronic acid on the activity of osteoclasts was different. The inhibition effect was obvious at 1×10–6 mol/L. We should pay attention to administrate appropriate concentration of zoledronic acid in the clinical applications.
Citation：
LIPengfei, YANGHu, JIANan, JINXianhui, XUDaokuan, SHENYaxin, ZHANGWei. Experimental study on inhibitory effect of zoledronic acid on the action style of the osteoclast. Journal of Biomedical Engineering, 2017, 34(1): 78-82. doi: 10.7507/1001-5515.201601041
Copy
Copyright © the editorial department of Journal of Biomedical Engineering of West China Medical Publisher. All rights reserved
| 1. |
Insalaco L, Di Gaudio F, Terrasi M, et al. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med, 2012, 16(9): 2186-2195.
|
| 2. |
郑小飞, 尹庆水, 杨传红, 等. 双膦酸盐诱导骨巨细胞瘤细胞凋亡的实验研究. 临床肿瘤学杂志, 2011, 16(3): 219-222.
|
| 3. |
李鹏飞, 靳宪辉, 李华, 等. 双膦酸盐类药物治疗脊柱骨巨细胞瘤二例报告. 中华肿瘤防治杂志, 2012, 19(8): 627-628.
|
| 4. |
Soki F N, LI Xin, Berry J, et al. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem, 2013, 114(1): 67-78.
|
| 5. |
Murphy C M, Schindeler A, Gleeson J P, et al. A collagen-hydroxyapatite scaffold allows for binding and co-delivery of recombinant bone morphogenetic proteins and bisphosphonates. Acta Biomater, 2014, 10(5): 2250-2258.
|
| 6. |
Brennan M A, Gleeson J P, O'brien F J, et al. Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution. J Mech Behav Biomed Mater, 2014, 29: 161-170.
|
| 7. |
郑小飞, 尹庆水, 杨传红, 等. 唑来膦酸诱导骨巨细胞瘤基质细胞向成骨细胞分化的实验研究. 临床肿瘤学杂志, 2011, 16(2): 128-133.
|
| 8. |
Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Hormone and Metabolic Research, 2012, 44(12): 909-913.
|
| 9. |
Das S, Edwards P A, Crockett J C, et al. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells. Biochim Biophys Acta, 2014, 1841(4): 569-573.
|
| 10. |
Dedes P G, Kanakis I, Gialeli C, et al. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochim Biophys Acta, 2013, 1830(6): 3625-3634.
|
- 1. Insalaco L, Di Gaudio F, Terrasi M, et al. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med, 2012, 16(9): 2186-2195.
- 2. 郑小飞, 尹庆水, 杨传红, 等. 双膦酸盐诱导骨巨细胞瘤细胞凋亡的实验研究. 临床肿瘤学杂志, 2011, 16(3): 219-222.
- 3. 李鹏飞, 靳宪辉, 李华, 等. 双膦酸盐类药物治疗脊柱骨巨细胞瘤二例报告. 中华肿瘤防治杂志, 2012, 19(8): 627-628.
- 4. Soki F N, LI Xin, Berry J, et al. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem, 2013, 114(1): 67-78.
- 5. Murphy C M, Schindeler A, Gleeson J P, et al. A collagen-hydroxyapatite scaffold allows for binding and co-delivery of recombinant bone morphogenetic proteins and bisphosphonates. Acta Biomater, 2014, 10(5): 2250-2258.
- 6. Brennan M A, Gleeson J P, O'brien F J, et al. Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution. J Mech Behav Biomed Mater, 2014, 29: 161-170.
- 7. 郑小飞, 尹庆水, 杨传红, 等. 唑来膦酸诱导骨巨细胞瘤基质细胞向成骨细胞分化的实验研究. 临床肿瘤学杂志, 2011, 16(2): 128-133.
- 8. Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Hormone and Metabolic Research, 2012, 44(12): 909-913.
- 9. Das S, Edwards P A, Crockett J C, et al. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells. Biochim Biophys Acta, 2014, 1841(4): 569-573.
- 10. Dedes P G, Kanakis I, Gialeli C, et al. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochim Biophys Acta, 2013, 1830(6): 3625-3634.
